In this episode, Michael goes it alone, welcoming an old friend of the show, Dr Belinda Yeo, to discuss highlights in early breast cancer from ASCO 2025. The pair discuss an exciting new medication to assist with vasomotor symptoms from endocrine therapy, the ongoing follow up from the pivotal SOFT/TEXT study, an escalation strategy for abemaciclib and a de-escalation strategy for neoadjuvant chemotherapy in HER2 positive breast cancer.

Studies discussed in this episode

OASIS

SOFT/TEXT, 15 year update

TRADE

NeoCARHP

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.